Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 2, 2014
Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to...
-
Jan 2, 2014FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist
Eisai Inc. announced today that FYCOMPA™ (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning...
-
Dec 9, 2013Seeking indication for prevention of chemotherapy-induced nausea and vomiting
Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the...
-
Dec 5, 2013
Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual...
-
Dec 4, 2013
Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer...